Immunological Profile of Solid Tumors Sample

• Conditions: Solid Cancer
• Interventions: Other: immunohistochemistry assay

• Registration Number: NCT03311100
• Lead Sponsor: Assistance Publique Hopitaux De Marseille

Brief Summary

It has become clear in the recent year that the nature of the immune cells infiltrate within a tumor was essential in the control of the tumor growth. This so-called immune contexture does vary between cancer types and in response to treatments. In this context, this trial is a non-interventional, mono-centric in patients with solid tumors. Samples in paraffin-embedded material block of biopsies or surgical pieces (either primitive tumor or metastases) will be analysed. For each sample, clinically relevant data associated with treated cancer and needed for characterization of tumor microenvironment will be documented.

This trial is, through accessing to well documented selected archival tumor materials, to validate selected biomarker for early phase trial.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-04-06
• Study First Submitted: 2017-10-11
• Study First Submitted QC: 2017-10-11
• Study First Posted: 2017-10-16
• Status Verified: 2018-01
• Last Update Submitted: 2018-01-29
• Last Update Posted: 2018-01-30
• Primary Completion: 2019-04-06
• Study Completion: 2020-04-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1040

Inclusion Criteria

• Sample must have had a valid written informed consent for available archival tumor samples for scientific purposes.
• Sample from patients with histologically documented cancer in target population.

Exclusion Criteria

• Samples from subject unwilling to give their informed consent;
• Unusable sample or biologically deteriorated.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Skin cancers	immunohistochemistry assay	-
Urothelial cancer	immunohistochemistry assay	-
Central Nervous System Cancers	immunohistochemistry assay	-
Head and Neck and upper aero-digestive tract cancers	immunohistochemistry assay	-
Sarcomas	immunohistochemistry assay	-
Hepatocarcinoma	immunohistochemistry assay	-
Lung cancer	immunohistochemistry assay	-

Primary Outcome Measures

Name	Time	Method
Immunohistochemistry scores	24 months	The immunohistochemistry scores is evaluated with the score of the staining intensity.; Staining Intensity: from 0 to 3 0 : no staining (absence); 1. : low staining; 2. : middle staining; 3. : high staining

Trial Locations

Locations (1)

Assistance Publique Hôpitaux de Marseille; 🇫🇷 Marseille, France